Product Data?SheetVoriconazoleCat. No.:CAS No.:分?式:分?量:作?靶点:作?通路:储存?式:HY-76200137234-62-9C??H??F?N?O349.31FungalAnti-infectionPowderIn solvent-20°C4°C-80°C-20°C3 years2 years6 months1 monthInhibitors?Agonists?Screening Libraries溶解性数据体外实验DMSO : ≥ 50 mg/mL (143.14 mM)H2O : 0.17 mg/mL (0.49 mM; Need ultrasonic)* \Mass1 mg5 mg10 mgSolventConcentration制备储备液1 mM5 mM10 mM2.8628 mL0.5726 mL0.2863 mL14.3139 mL2.8628 mL1.4314 mL28.6279 mL5.7256 mL2.8628 mL请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;?旦配成溶液,请分装保存,避免反复冻融造成的产品失效。储备液的保存?式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个?内使?,-20°C 储存时,请在 1 个?内使?。体内实验请根据您的实验动物和给药?式选择适当的溶解?案。以下溶解?案都请先按照 In Vitro ?式配制澄清的储备液,再依次添加助溶剂: 为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的?作液,建议您现?现配,当天使?; 以下溶剂前显?的百分?是指该溶剂在您配制终溶液中的体积占?;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的?式助溶1. 请依序添加每种溶剂:?10% DMSO ?? 40% PEG300 ?? 5% Tween-80 ?? 45% salineSolubility: ≥ 2.5 mg/mL (7.16 mM); Clear solution此?案可获得 ≥ 2.5 mg/mL (7.16 mM,饱和度未知) 的澄清溶液。 以 1 mL ?作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加? 50 μL Tween-80,混合均匀;然后继续加? 450 μL ?理盐?定容? 1 mL。2. 请依序添加每种溶剂:?10% DMSO ?? 90% (20% SBE-β-CD in saline)Solubility: ≥ 2.5 mg/mL (7.16 mM); Clear solutionPage 1 of 2 www.MedChemExpress.cn
此?案可获得 ≥ 2.5 mg/mL (7.16 mM,饱和度未知) 的澄清溶液。
以 1 mL ?作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD ?理盐??溶液中,混合均匀。
3. 请依序添加每种溶剂:?10% DMSO ?? 90% corn oilSolubility: ≥ 2.5 mg/mL (7.16 mM); Clear solution
此?案可获得 ≥ 2.5 mg/mL (7.16 mM,饱和度未知) 的澄清溶液,此?案不适?于实验周期在半个?以上的实验。 以 1 mL ?作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL ??油中,混合均匀。
BIOLOGICAL ACTIVITY
?物活性
Voriconazole(UK-109496)是第?代三唑类抗真菌化合物,可作?于严重的真菌感染。
客户使?本产品发表的科研?献
????Med Mycol. 2018 Jun 1;56(4):452-457.
See more customer validations on www.MedChemExpress.cnREFERENCES
[1].?Mikus G, Scholz IM, Weiss J. Pharmacogenomics of the triazole antifungal agent voriconazole. Pharmacogenomics. 2011 Jun;12(6):861-72. doi: 10.2217/pgs.11.18.
[2].?Scholz I, Oberwittler H, Riedel KD, et al. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. Br J Clin Pharmacol. 2009 Dec;68(6):906-15. doi: 10.1111/j.1365-2125.2009.03534.x.
[3].?Herbrecht R. Voriconazole: therapeutic review of a new azole antifungal. Expert Rev Anti Infect Ther. 2004 Aug;2(4):485-97.
[4].?Louis D. Saravolatz, Section Editor, Leonard B. Johnson, et al. Voriconazole: A New Triazole Antifungal Agent. Clin Infect Dis. 2003,36 (5): 630-637.[5].?John R. Perfect, Kieren A. Marr, Thomas J. Walsh, et al. Voriconazole Treatment for Less-Common, Emerging, or Refractory Fungal Infections. Clin Infect Dis. 2003, 36 (9): 1122-1131.
McePdfHeightCaution: Product has not been fully validated for medical applications. For research use only.
Tel: 400-820-3792; 021-58955995 Fax: 021-53700325 E-mail: tech@MedChemExpress.cn
Master of Small Molecules — 您?边的抑制剂?师
Page 2 of 2 www.MedChemExpress.cn
伏立康唑作用机制- Medchemexpress- MCE中国
![](/skin/haowen/images/icon_star.png)
![](/skin/haowen/images/icon_star.png)
![](/skin/haowen/images/icon_star.png)
![](/skin/haowen/images/icon_star.png)